virologic monitoring during art
DESCRIPTION
Virologic monitoring during antiretroviral therapyTRANSCRIPT
![Page 1: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/1.jpg)
Virologic Monitoring during ART
Davey Smith, M.D., M.A.S.Associate Professor of Medicine
Director CFAR Translational Virology CoreUniversity of California San Diego
![Page 2: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/2.jpg)
2
Viral Load
CD4+ Cells
Time After Infection
Clinical Course of HIV Infection
Anti-retroviralTherapy
![Page 3: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/3.jpg)
3
Viral Load
CD4+ Cells
Time After Infection
Clinical Course of HIV Infection
Anti-retroviralTherapy
Treatment Failure
![Page 4: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/4.jpg)
Consequences of HAART Failure
Virologic Rebound Increased Transmission End Organ Damage (Nervous system,
Cardiovascular, Liver, Renal, etc.) Immune System Deterioration
OIs, Cancers Drug Resistance
Transmitted Resistance
Tuyama A, et al. CROI 2008. Abstract 57; Letendre S. CROI 2008. Abstract 68. Little et al. NEJM 2002; Wawer, et al. JID 2005
![Page 5: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/5.jpg)
Goals of Current HAART HAART really only works on the virus to
decrease or ‘stop’ replication Measured by viral loads
5
![Page 6: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/6.jpg)
Goals of Current HAART HAART really only works on the virus to
decrease or ‘stop’ replication Measured by viral loads
Stopping viral replication hopefully stops or slows the destruction of CD4 cells, allowing them to rebound. Measured by CD4 counts
6
![Page 7: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/7.jpg)
Goals of Current HAART HAART really only works on the virus to
decrease or ‘stop’ replication Measured by viral loads
Stopping viral replication hopefully stops or slows the destruction of CD4 cells, allowing them to rebound. Measured by CD4 counts
Rebounding CD4 counts restores immune function. Measured by symptoms or presence of OIs
7
![Page 8: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/8.jpg)
Monitoring Strategies Symptomatic
Immunologic (CD4 counts)
Virologic (Viral Loads)
8Bendavid, E. et al. Arch Intern Med 2008;168:1910-1918.
![Page 9: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/9.jpg)
WHO criteria for ART Failure:
1) CD4 cell count falls below baseline in the absence of other concurrent infections,
2) CD4 cell count falls to less than 50% of peak CD4 levels without concurrent infections, or
3) CD4 cell count is ‘consistently’ below 100 cells/ml.
![Page 10: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/10.jpg)
The association between a falling CD4 count and virological failure
Changes in CD4 count correlated well with detectable viral load but had very poor sensitivity.
“Thus, CD4 cell count measurements cannot be used as a substitute for early virological failure monitoring.”
10Badri, Lawn and Wood. BMC Infect Dis. 2008 Jul 4;8:89
![Page 11: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/11.jpg)
Risk of Delayed HAART Switch
SCOPE cohort of ART-experienced subjects (n = 106)[1]
Stable HAART for 120 days HIV-1 RNA > 1000 c/mL 1 resistance mutation Resistance testing every 4 mos
until HAART modification
Emergence of new RAMs at 1 yr Any: 44% (95% CI: 33%-56%) NAMs: 23% (95% CI: 15%-34%) PI: 18% (95% CI: 9%-34%)
1. Hatano H, et al. CROI 2006. Abstract 615. 2. Lafeuillade A, et al. IAC 2004. Abstract WeOrB1293. 3. Margot NA, et al. JAIDS. 2003;33:15-21. 4. Napravnik S, et al. JAIDS. 2005;40:34-40. 5. Eron J. IAS Strategies for Antiretroviral Failure
Prop
ortio
n W
ithou
t N
ew M
utat
ion
1 new major PI mutation1 new NRTI mutation*Any new mutation
Number of available antiretrovirals from the following: ZDV, 3TC, ddI, ABC,TDF, EFV, IDV, NFV, SQV, RTV, APV, LPV
0
0.25
0.50
0.75
1.00
0 4 8 12 16 20 24Time (Mos)
Time to loss of 1 drug equivalent
Prop
ortio
n W
ithou
t Lo
ss o
f 1 D
rug
0 4 8 12 16 20 24
*PI-treated subjects (n = 71)0
0.25
0.50
0.75
1.00
![Page 12: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/12.jpg)
Probability of Drug Resistance in First-line HAART Failure
Harrigan et al. J Infect Dis. 2005;191:339-347.
![Page 13: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/13.jpg)
Disclosure
I am completely biased that virologic monitoring should be
used during HAART.
![Page 14: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/14.jpg)
14
Bendavid, E. et al. Arch Intern Med 2008;168:1910-1918.
CD4-based strategies resulted in higher life expectancy and were less costly than the symptom-based approaches.
![Page 15: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/15.jpg)
15
Bendavid, E. et al. Arch Intern Med 2008;168:1910-1918.
Adding viral load to CD4 count monitoring was associated with further increase in life expectancy. VL every 6 months was associated with a 2-month gain in life expectancy. VL was associated with an increased lifetime cost of $899 per person VL every 3 months vs. every 6 months was associated with modest increases in life
expectancy and significant increases in lifetime costs.
![Page 16: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/16.jpg)
And the data keep coming in-Rawizza CID Dec. 2011
16
![Page 17: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/17.jpg)
Mermin et al. Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial BMJ 2011
17
![Page 18: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/18.jpg)
Mermin et al. Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial. BMJ 2011
18
The issues are:•Morbidity lags behind both VL and CD4 •Does not take into account transmitted resistance
![Page 19: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/19.jpg)
Projected costs of Viral Load Monitoring
19
Annual Cost (US$)*
Percent of Total HIV Spending§
Low and Middle Income CountriesVL every 3 months (already on ART) $540,000,000 5.4%VL every 6 months (already on ART) $270,000,000 2.7%VL every 3 months + ART (all eligible) $3,667,741,801 36.7%VL every 6 months + ART (all eligible) $2,796,774,091 28%VL = viral load; *Based on estimated cost of US$45 per viral load assay (Bendavid et al.12); §Figures for global and Mozambican spending for 2007 and 2008 from UNAIDS11
and UNGASS14 respectively
From M. Tilghman 2011
![Page 20: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/20.jpg)
If we are going to measure viral replication during HAART, can we do it efficiently?
![Page 21: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/21.jpg)
Virologic MonitoringMethod Parameter Measured Expensive Needs Clinical
ValidationRoche Molecular
Systems (AmplicorMonitor, RealTime)
HIV-1 RNA X
Abbott RealTime HIV-1 RNA XBayer bDNA HIV-1 RNA X
Biomerieux (Nuclisens) HIV-1 RNA XPerkin Elmer p24 XCavidi ExaVir Reverse Transcriptase
ActivityX
Homebrew RealTime HIV-1 RNA XFlowcytometry HIV-1 RNA X
21
![Page 22: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/22.jpg)
Can we make currently validated methods cheaper?
22
![Page 23: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/23.jpg)
Pooling Methods Rationale Viral loads can identify people with acute infection. Because testing for HIV RNA in each blood
sample would be expensive, they pooled blood samples and performed one viral load assay on a pooled sample.
If the sample was negative, then most likely all individuals in the pool were negative.
Can be used with any quantitative viral load method.
23
![Page 24: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/24.jpg)
Methods: Quantitative Monitoring
24
Eligibility: HIV-infected patients receiving ART x 6 months
Pooling: Minipools or Matrix of samples
Quantify: Standard viral loads of pools
Negative Positive
All samples with viral loads <500 copies/ml
At least one sample with viral load above threshold
Pooling AlgorithmNegative
Positive
Samples with virologic failure= deconvolute
![Page 25: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/25.jpg)
Minipools
May et al. JAIDS 2009
![Page 26: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/26.jpg)
Matrix Strategy Individual samples are
pooled (hexagons) vertically (A-J) and horizontally (1-10), and viral load tests are run first on the pooled samples only.
Ambiguous samples would then have to be resolved.
1 2 3 4 5 6 7 8 9 10ABCDEFGHIJ
Pools 1-10
Pools A-J
![Page 27: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/27.jpg)
Example VL Output from a Pooled Matrix
Matrix Position
NAT Viral Load
Row 1= 0Row 2= 2700Row 3= 1500Row 4= 0Row 5= 0Row 6= 0Row 7= 0Row 8= 0Row 9= 0Row 10= 0
Column 1= 0Column 2= 0Column 3= 0Column 4= 2200Column 5= 0Column 6= 0Column 7= 2000Column 8= 0Column 9= 0Column 10= 0
1 2 3 4 5 6 7 8 9 10A B C D E F G H I J
Pools 1-10
Pools A-J
Ambiguous
samples in gray
![Page 28: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/28.jpg)
Resolving the ambiguous samples is kind of like Sudoku….
28
Matrix Formula (=If Ax1>0,”A+1”/2 based on the previous VL output)
Re-testIndividually test the samples with the largestestimated viral loads
![Page 29: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/29.jpg)
Example VL Output from a Pooled Matrix
Matrix Position
NAT Viral Load
Row 1= 0Row 2= 2700Row 3= 1500Row 4= 0Row 5= 0Row 6= 0Row 7= 0Row 8= 0Row 9= 0Row 10= 0
Column 1= 0Column 2= 0Column 3= 0Column 4= 2200Column 5= 0Column 6= 0Column 7= 2000Column 8= 0Column 9= 0Column 10= 0
1 2 3 4 5 6 7 8 9 10A B C D E F G H I J
Pools 1-10
Pools A-J
Ambiguous
samples in gray
![Page 30: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/30.jpg)
Resolve Ambiguities The ambiguous samples would be
A4, A7, B4, B7 Perform a viral load test on the
individual sample with the highest viral load in the matrix formula (A4)
The actual viral load for this sample is 700 copies/ml.
![Page 31: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/31.jpg)
Resolve Ambiguities Now, subtract the
viral load value of A4 (700) from column A and row 4.
The output is now:
Matrix Position
NAT Viral Load
1= 02= 03= 04= 20005= 06= 07= 15008= 09= 010= 0
A= 1500B= 2000C= 0D= 0E= 0F= 0G= 0H= 0I= 0J= 0
![Page 32: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/32.jpg)
Resolve Ambiguities The ambiguous samples would be
A7, B4, B7 Again, perform a viral load test on the
individual sample with the highest viral load in the matrix formula (B4)
The actual viral load for this sample is 2000 copies/ml.
![Page 33: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/33.jpg)
Resolve Ambiguities
Now, subtract the viral load value of B4 (2000) from column B and row 4.
The output is now: Last VL of a sample is
1500.
Matrix Position
NAT Viral Load
1= 02= 03= 04= 05= 06= 07= 15008= 09= 010= 0
A= 1500B= 0C= 0D= 0E= 0F= 0G= 0H= 0I= 0J= 0
![Page 34: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/34.jpg)
34
![Page 35: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/35.jpg)
35
Matrix Position
NAT Viral Load
Row 1= 0Row 2= 0Row 3= 0Row 4= 2700Row 5= 0Row 6= 0Row 7= 1500Row 8= 0Row 9= 0Row 10= 0
Column 1= 2200Column 2= 2000Column 3= 0Column 4= 0Column 5= 0Column 6= 0Column 7= 0Column 8= 0Column 9= 0Column 10= 0
![Page 36: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/36.jpg)
36
Re-Test Value-1
![Page 37: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/37.jpg)
37
Re-Test Value-2
![Page 38: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/38.jpg)
38
Re-Test Value-3
![Page 39: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/39.jpg)
39
![Page 40: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/40.jpg)
40
![Page 41: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/41.jpg)
41
![Page 42: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/42.jpg)
May et al. AIDS 2009.
Modeling Study
![Page 43: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/43.jpg)
May et al. AIDS 2009.
Modeling Study
![Page 44: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/44.jpg)
San Diego Pooled VL Study We compared performing viral loads on:
individual samples,10x10 matrix, minipools of 5 Pooling algorithm thresholds for detecting
HAART failure were set at: Minipools of 5 : <250 and <500 copies/mL 10x10 Matrix: <500 and <1500 copies/mL
150 individuals on HAART with a prevalence of HAART failure of 23%
44
![Page 45: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/45.jpg)
Smith et al. AIDS 2009.
San Diego Pooled Study
![Page 46: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/46.jpg)
Turn Around Time
46
Even though it took 17 days on average to completely resolve the matrix, 66% of all samples were resolved the first day
![Page 47: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/47.jpg)
Mexico Pooled Study
47Tilghman et al. JAIDS 2010
Test characteristics of 10x10 matrix pooling platform compared to individual viral load testing
Negative Predictive Value (%)All Matrices
*VF = 500 c/mL>50 c/mL 90%>500 c/mL 90%>1,000 c/mL 90%>1,500 c/mL 91%
*VF = 1500 c/mL>50 c/mL 89%>500 c/mL 89%>1,000 c/mL 90%>1,500 c/mL 91%
•700 patients
•Unknown HAART use
•22% with detectable VL some with high VL
•One matrix identified with contamination
•Still with 33% cost savings ($14,000)
![Page 48: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/48.jpg)
South Africa Pooled Study
48
Method Prevalence of failure
(> 1000 copies/ml )
Negative
predictive value
Relative efficiency
(reduction in tests
needed)
Cost savings per
100 specimens
3 matrices
(n=300) 11% 98% 41% US$ 1640
80 minipools
(n=400) 9.50% 100% 30.5% US$ 1220
Van Zyl et al. CID 2011
![Page 49: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/49.jpg)
49
Issues
Viral loads are better to detect HAART failure than symptoms or CD4 trajectory but VLs are expensive
Unrecognized HAART failure can lead to drug resistance for the patient and the population
Clinically-relevant level of VL detection Prevalence of HAART failure in the local population Viral load assay variability
Haubrich R and Saag M. IAS Workshop 2008
![Page 50: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/50.jpg)
Maybe a new test?
A Combined Screening Platform for HIV Treatment Failure and ResistanceTilghman et al. PLoS One 2012.
50
![Page 51: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/51.jpg)
Methods: Qualitative Monitoring
51
Eligibility: HIV-infected patients receiving ART x 6 months
Pooling: Minipools of 5 samples O+O+O+O+O→ [O]
PCR: RT-PCR of HIV-1 RT in pool → cDNA → PCR of RT
Negative Positive
All samples with viral loads <500 copies/ml
At least one sample with viral load >500 copies/ml
PCR each sampleNegative
Positive
Samples with viral loads <500 copies/ml
Sequence PCR product for genotype
![Page 52: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/52.jpg)
Table 1. Patient demographic data (for n = 171 patients).
Tilghman MW, May S, Pérez-Santiago J, Ignacio CC, et al. (2012) A Combined Screening Platform for HIV Treatment Failure and Resistance. PLoS ONE 7(4): e35401. doi:10.1371/journal.pone.0035401http://www.plosone.org/article/info:doi/10.1371/journal.pone.0035401
![Page 53: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/53.jpg)
Table 2. Treatment and laboratory data for samples (n = 295)*.
Tilghman MW, May S, Pérez-Santiago J, Ignacio CC, et al. (2012) A Combined Screening Platform for HIV Treatment Failure and Resistance. PLoS ONE 7(4): e35401. doi:10.1371/journal.pone.0035401http://www.plosone.org/article/info:doi/10.1371/journal.pone.0035401
![Page 54: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/54.jpg)
Figure 1. Test characteristics of qualitative pooled RT assay in the detection of varying levels of virologic failure using first round of PCR only.
Tilghman MW, May S, Pérez-Santiago J, Ignacio CC, et al. (2012) A Combined Screening Platform for HIV Treatment Failure and Resistance. PLoS ONE 7(4): e35401. doi:10.1371/journal.pone.0035401http://www.plosone.org/article/info:doi/10.1371/journal.pone.0035401
![Page 55: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/55.jpg)
Considerations for Choosing a Strategy to Detect Virologic Failure
Factors Costs Clinical Considerations
Assay type and level of detection
Cost per assay Accuracy
Inherent error of assay type
Cost per assay Accuracy
Laboratory space to avoid contamination during processing
Space cost Quality assurance
Personnel availability Personnel cost Turnaround timePersonnel training Personnel cost Quality assuranceClinic population Size Cost per pool Turnaround timeRate of virologic failure Cost per pool AccuracyRate of screening Cost per pool Accuracy and Turnaround
time
![Page 56: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/56.jpg)
Pooling Experiments
56
![Page 57: Virologic monitoring during ART](https://reader034.vdocuments.mx/reader034/viewer/2022051610/549e7741b37959744b8b45c9/html5/thumbnails/57.jpg)
Acknowledgements
Winston Tilghman Josué Pérez Santiago Connie Benson Richard Haubrich Susan Little Susanne May Douglas Richman Chip Schooley
Emilia Noormahomed(Mozambique)
KumarasamyNagalingeswaran (India)
Saravanan Shanmugam(India)
Gert van Zyl (South Africa) Don Diego Guerena (Mexico) Jun Yong Choi (South Korea)